Quetiapine in Prevention of Delirium

Role of Quetiapine in the Prevention of ICU Delirium in Elderly Patients at a High Risk

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05793632

Enrollment

Registered

2023-03-31

Start date

2023-03-01

Completion date

2023-04-15

Last updated

2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium

Brief summary

The aim is to study the effectiveness of Quetiapine in preventing delirium in the elderly patients with multiple risks for delirium.

Interventions

DRUGQuetiapine

The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

60 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with anemia * Sedated patients * Hypotensive patients * Immobilized patients * Patients with visual or auditory impairment

Exclusion criteria

* Patients or guardians refuse to participate * Patients diagnosed with delirium * Contraindication for delirium

Design outcomes

Primary

Measure	Time frame	Description
Quetiapine in preventing delirium	2 months	The presence of delirium will be monitored among the patients in the two groups using ICU-Confusion Assessment Method 7 score for delirium where a score of (0-2 = no delirium, 3-5 = mild to moderate delirium and a score \>5 = severe delirium)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026